

INVITATION

**From Target Discovery to
Precision Medicine – the Unique
Potential of Finnish Biobanks
in Biomedical Research**

30TH SEPTEMBER 2024

WELCOME TO SYMPOSIUM

From Target Discovery to Precision Medicine – the Unique Potential of Finnish Biobanks in Biomedical Research

Join us for an insightful dive into biomedical research in collaboration with Finnish biobanks & world-class experts!

30TH OF SEPTEMBER AT 17:30–20:15 (EET)
4.30pm–7.15pm (CET)
11.30am–2.15pm (ET, US)

ONLINE: Webinar link provided after registration

ON-SITE: Hilton Helsinki Kalastajatorppa, Siirtomaasali
Kalastajatorpantie 1, 00330 Helsinki
Networking & buffet after symposium

Spanning from target discovery to personalized medicine in action, the symposium offers a spectrum of **real-life biomedical research cases in neurology, immunology, oncology, ophthalmology, and rare diseases**, and elucidates the research opportunities that Finnish biobanks and the unique genetic heritage of Finns provide.

The symposium brings together professionals from pharma, biotech, and academia from all over the world – You are warmly welcome online or in person!

Marco Hautalahti
CEO, FINBB – Finnish Biobanks

PROGRAMME *(in Eastern European time, EET)*

- 17:30** **Welcome and opening words by the Chairman**
Timo Veromaa, Professor of Practice, University of Turku
- 17:40** **Biobanks and yet undiscovered Finnish disease heritage – a treasure trove?**
Mikko Seppänen, Associate Professor of Internal Medicine, Chief Physician, HUS Rare Diseases Center
- 18:00** **Characterising rare Complement Factor I genetic variants in Finnish dry AMD to support clinical development of retinal gene therapy, a FINBB research collaboration with Gyroscope Therapeutics, a Novartis company**
Amy Jones, Director of Clinical Genetics, Gyroscope Therapeutics
- 18:40** **Studies in motor neuron disease ALS and multiple sclerosis**
Pentti Tienari, Professor of Neuroimmunology, Chief Neurologist, Helsinki University Hospital
- 19:05** **Implementing precision oncology: Role of big data and biobanks**
Kimmo Porkka, Professor of Personalized Cancer Medicine, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, and Chief Physician, Helsinki University Hospital Comprehensive Cancer Center
- 19:25** **Lifetime Cost-Effectiveness of Breast and Ovarian Cancer Prevention among Biobank Sample Donors with Hereditary BRCA1, BRCA2, or PALB2 Mutations**
Erkki Soini, CEO, ESIOR Oy and Chairman of the Board, Kuopio Health
- 19:45** **Fingenious® - Your Gateway to Finnish Biobanks and Biomedical Research**
Johanna Mäkelä, PhD, Director of Research and Services, FINBB – Finnish Biobanks
- 20:05** **Discussion and closing words by the Chairman**
Timo Veromaa, Professor of Practice, University of Turku
- 20:15** **ON-SITE: Networking and buffet**

REGISTER BY SEPT 15TH AT: www.fingenious.fi

Please register soon – seats on-site are limited.



Additional information:

meri.lahtenmaki@finbb.fi / +358 40 504 7778